Skip to content

Effects of SGLT2 inhibitors on cognitive impairment in elderly patients with heart failure with reduced ejection fraction:A prospective cohort study

Effects of SGLT2 inhibitors on cognitive impairment in elderly patients with heart failure with reduced ejection fraction:A prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066070
Enrollment
Unknown
Registered
2022-11-23
Start date
2022-11-23
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment in elderly patients with heart failure with reduced ejection fraction

Interventions

0ne:None

Sponsors

The First Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients with aged 65 years or older 2. New York Heart Function Rating NYHA Grade II-IV 3. Left ventricular ejection fraction < 40% 4. Increased N-terminal precursor natriuretic peptide 5. Montreal Cognitive Assessment Scale < 26 points

Exclusion criteria

Exclusion criteria: 1. Acute decompensated heart failure within one week requires intravenous diuretic, vasodilator or positive inotropic drugs 2. Coronary artery bypass grafting, aortic valve replacement or other major cardiovascular surgery within the last 3 months 3. A variety of serious diseases that affect the clinical course of the subjects, such as acute exacerbation, acute and chronic obstructive pulmonary disease Liver disease, severe renal impairment (eGFR<30mL/min/1.73m2 or regular dialysis subjects), severe anemia, Acute or chronic pancreatitis, present urinary or reproductive infections, any recorded activity or symptoms in the year prior to screening Suspected malignancy or history of malignancy 4. With the exception of heart failure, the researchers identified any disease that caused life expectancy to be less than 1 year 5. Failure to adhere to the study evaluation time for follow-up, or according to the investigator's clinical judgment is not suitable for the trial

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment Scale;

Secondary

MeasureTime frame
mini-mental state examination;left ventricular ejection fraction;N-terminal precursor brain natriuretic peptide;6-min walking distance;

Countries

China

Contacts

Public ContactYao Simin

The First Hospital of Shanxi Medical University

m18811586001@163.com18811586001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026